Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics develops cell and exosome-based therapeutics for rare diseases, with Deramiocel, an allogeneic cardiac-derived cell therapy, as its lead program for Duchenne muscular dystrophy. Company news commonly covers HOPE-3 clinical data, Biologics License Application communications with the FDA, regulatory designations for Deramiocel, and manufacturing activities tied to the DMD program.
Updates also include financial results, corporate presentations at neurology and muscular dystrophy medical meetings, collaboration revenue references tied to its U.S. Distribution Agreement with Nippon Shinyaku, and preclinical work using the StealthX exosome platform for vaccinology and delivery of oligonucleotides, proteins, and small-molecule therapeutics.
Capricor Therapeutics (NASDAQ: CAPR) announced its participation in the upcoming BIO Digital International Convention from June 8-12, 2020. The event, transitioning to a virtual format, will connect global biotech partners through one-on-one meetings and educational resources. Capricor focuses on developing innovative biological therapeutics, including its lead candidate CAP-1002 for treating Duchenne muscular dystrophy and COVID-19. For more details, visit Capricor's Investor Relations page.
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, announced CEO Linda Marbán's participation in a panel on cell therapy for ARDS on May 27 at 10:00 AM ET. This discussion, part of a session hosted by Maxim Group and M-Vest, will address the role of cell therapy in treating acute respiratory distress syndrome, particularly in the context of COVID-19. Capricor is developing CAP-1002, a cell therapy for Duchenne muscular dystrophy and COVID-19, while also exploring exosome-based treatments. The company emphasizes its commitment to innovation in biological therapeutics.
Capricor Therapeutics (NASDAQ: CAPR) announced positive results from the Phase II HOPE-2 study of CAP-1002 for DMD, showing significant improvements in upper limb performance (p=0.05) and cardiac function (p=0.004). The FDA has approved an expanded access program to treat additional COVID-19 patients, with the compassionate use cases reporting 100% survival. The company reported a net loss of $2.1 million for Q1 2020 but raised $12.8 million through offerings. Capricor plans to discuss the DMD approval pathway with the FDA and is expanding its vaccine platform against COVID-19.
Capricor Therapeutics (NASDAQ: CAPR) will release its Q1 2020 financial results after market close on May 14, 2020. A conference call and webcast for discussion will be held at 4:30 p.m. ET the same day. The company specializes in developing first-in-class biological therapeutics, notably its lead candidate CAP-1002, an allogeneic cell therapy aimed at treating Duchenne muscular dystrophy. Further details about its products and business strategy will be communicated during the event.
Summary not available.